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hyperlipidemia based on the standardized interview conducted by the National
Center for Health Statistics (NCHS) among adults  18 years. Descriptive statistics
and multivariate logistic regression were used to determine predictors having the
combined diagnosis including the following independent variables: gender, age,
race, ethnicity, urban/rural status and smoking status. Statistical analysis was
performed using SAS 9.2. RESULTS: The total sample included 33,994 individuals
and the combined diagnosis of hypertension and hyperlipidemia was reported in
4.49% of the sample. Of these, 61.51% were females and 41% were aged between
60-75 years. Most (73.25%) of these patients were whites and more than half
(54.75%) reported to have smoked at least 100 cigarettes in their lifetime, while
34.01% were current smokers. In the multivariate model, significant predictors of
the combined diagnosis included female gender (OR 0.689; 95% CI 0.594 – 0.798;
p.0001), age 60-75 years vs. younger age (OR1.627; 95% CI1.296 – 2.042;
p.0001),MexicanAmerican race vs. non-hispanics (OR 0.611; 95%CI 0.49 – 0.76;
p.0007) and current smokers. (OR1.374; 95% CI1.08-1.75; p.0001).
CONCLUSIONS: Our findings emphasize the importance of developing effective
intervention strategies that help smokers quit and may reduce prevalence of hy-
perlipidemia with hypertension along with the accompanying cardiovascular risk.
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OBJECTIVES: Diabetes prevalence has grown rapidly in China. As the largest epi-
demiology and clinical outcomes assessment program, China Cardiometabolic
Registries (CCMR), has been designed to establish systemic evaluation on disease
progression and influencing factors. The Nationwide Assessment of CVD Risk Fac-
tors: Blood Pressure, Blood Lipid, and Blood Glucose, in Chinese Patients with type
2 Diabetes (T2D) (CCMR-3B) was one of the CCMR studies and was conducted to
assess the clinical outcomes of current treatment patterns.METHODS: This was a
cross sectional, observational study. Patients were recruited from community (tier
1), regional (tier 2), and teaching hospitals (tier 3) from all 6 major geographic
regions in China, by cardiologists, nephrologists and endocrinologist, and internal
medicine. RESULTS: A total of 5099 T2D patients was included for this analysis.
Across all hospitals, 55% and 34% of the patients had hypertension (HTN) or dis-
lipidemia (DYLP), respectively, while 33% had neither. No difference was found
between hospitals regarding the proportion of patients reaching target control
(HbA1C7.0%, BP130/80 mmHg, LDL2.6 mmol/L) in those who also have HTN or
DYLP (ranging from 4.4 % to 6.6% for the HTN group and 6.9% to8.0% for the DYLP
group). However a trend toward a better HbA1C control in patients without HTN or
DYLP (diabetes only) in larger hospitalswas seen (10.7%, 11.2%, 15.4% in tier 1, 2 and
3 hospitals, respectively). A trend toward more use of multiple oral anti-diabetic
drugs and insulin was also seen in larger hospitals. CONCLUSIONS: Better HbA1c
control seen in larger hospitals was associated with more aggressive use of antidi-
abetic treatment. The control of cardiovascular risk factors, blood glucose, blood
pressure, and blood lipid, in diabetes patients with HTN or DYLP remains to be
challenging in all hospital settings.
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OBJECTIVES: To study the predictors of beta-blocker therapy discontinuation
among post myocardial infarction (MI) patients enrolled in Medicare. METHODS:
This is a retrospective cohort study utilizing a Medicare 5% national sample claims
data for 2006-2007. Medicare beneficiaries with continuous Part A, B, and D enroll-
ment in 20062007, and who were hospitalized for an acute MI in the first six
months of 2006 were identified using a validated algorithm, requiring a hospital-
ization episode 3 and 180 days with an ICD-9-CM of 410.x1 as principal or sec-
ondary diagnosis. Post-MI patientswith a filled prescription for beta-blockerwithin
90 days of discharge were followed until the end of the study period. Time to
discontinuation was defined as days from initiation of therapy to a gap of90 days
in therapy. Survival curves were modeled using the Kaplan-Meier technique, and
potential predictors of therapy discontinuation, including demographic character-
istics, comorbid conditions and concomitant medications were estimated using
Cox proportional hazards regression. RESULTS: Of the 2,505 subjects who met our
inclusion criteria, 65.1% were females, 83.3% were Caucasian, mean age 78.6 (8.2)
years. About 15% of them discontinued therapywithin sixmonths and around 35%
discontinued within a year. Males weremore likely to discontinue therapy as com-
pared to females (HR1.166; [1.020-1.334]; p0.0245) and Caucasians (HR0.674;
[0.557-0.815]; p0.0001) were less likely to discontinue therapy compared to Afri-
can Americans. The results of Cox proportional hazardsmodel shows that diabetes
(HR1.224; [1.069-1.402]; p0.0035), dyslipidemia (HR0.675; [0.565-0.807];
p.0001), CHF (HR1.234; [1.03-1.478]; p0.0223), cerebrovascular disease
(HR1.206; [1.057-1.376]; p0.0054) and COPD (HR1.209; [1.061-1.377]; p0.0043)
were significant predictors of time to discontinuation. Patients on concomitant
statin treatment were less likely to discontinue beta-blocker therapy (HR0.774;
[0.667-0.899]; p0.0008). CONCLUSIONS: Many patients initiating beta-blocker
therapy post MI fail to consistently remain on the treatment. Several demographic
characteristics and comorbid conditions are associated with this behavior.
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OBJECTIVES: Adherence to chronic heart failure (CHF) medications decreases pre-
ventable hospitalizations. Nevertheless, CHF rarely occurs without concomitant
conditions. We sought to: 1) evaluate impact of comorbid depression on CHFmed-
ication use and adherence among Medicare beneficiaries with CHF(CHF_MED-
_BEN); 2) examine relationships between CHF medication adherence and out-
comes; and 3) determine if depression modifies this relationship. METHODS: We
employed a cross-sectional design of 2006-2007 CMS Medicare Chronic Condition
Warehouse (CCW) database. Sample was restricted to CHF_MED_BEN with Medi-
care A,B and D to observe all prescription and medical claims. We classified indi-
viduals with CHF and depression if theymet the CCWdefinitions. Adherencemea-
sures included any use (binary) and medication possession ratio (MPR) for
evidence-based CHF medications (EBM). Multivariable analyses included an inter-
action term to test effect modification of depression on the relationship between
EBM adherence and number of hospitalizations. Relative rates of hospitalization
are reported with 95%CI. RESULTS: A total of 151,924 CHF_MED_BENmet inclusion
criteria. Mean agewas 75.9/-12.0 years; 68%were female. 25%had depression and
they were significantly younger(74.5 vs. 76.3 years,p0.001) and more likely to be
female(75% vs. 66%,p0.001) compared to non-depressed CHF_MED_BEN. A signif-
icantly lower proportion of depressed CHF_MED_BEN received EBM (75% vs.
79%,p0.001), compared to non-depressed CHF_MED_BEN.MedianMPRwas 0.92 in
both groups. A higher proportion of depressed CHF_MED_BEN was hospitalized
(76% vs. 63%,p0.001) and re-hospitalized (40.5% vs. 38.6%,p0.001) compared to
non-depressed CHF_MED_BEN. In multivariable models, depression modified the
effect of adherence on hospitalizations (interaction term p0.001): compared to
high adherence (MPR0.9), poor adherence (MPR0.5) was associated with a 24%
(95%CI 1.20-1.28) increased hospitalization rate among non-depressed CHF_MED-
_BEN and a 45% (95%CI 1.37-1.54) increased hospitalization rate among depressed
CHF_MED_BEN. CONCLUSIONS: Depression was not associated with poor EBM ad-
herence among CHF_MED_BEN. Poor EBM adherence was associated with in-
creased hospitalization in both depressed and non-depressed groups, with a
greater effect among depressed CHF_MED_BEN.
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OBJECTIVES: To compare the performance of pulmonary arterial hypertension
(PAH) drug classes based on the risk of mortality reported in clinical trials, and
inform a revised PAH treatment algorithm. METHODS: The study used Bayesian
Analysis Using Gibbs Sampling in Windows (WinBUGS) and Monte Carlo Simula-
tions to conduct a multiple treatment comparison of placebo and three PAH drug
classes; prostanoids (Treprostinil & Iloprost), endothelin-receptor antagonists
(Bosentan, Sitaxsentan, & Ambrisentan), and phosphodiesterase (sildenafil). Direct
and indirect pairwise odds ratios (OR) were obtained. Published PAH studies
through 2010 were identified from MEDLINE (PubMed) database and an extended
manual search was also conducted based on references from identified studies.
Inclusion was restricted to randomized controlled trials lasting at least 12 weeks
and at most 16 weeks, with subjects having either idiopathic or associated PAH,
and studies that reported mortality as an endpoint. Studies that compared combi-
nations of drugs were excluded from the analysis. Results are reported in OR with
95% credible intervals. RESULTS: In total 8 studies (20 treatment arms, 2,015 sub-
jects enrolled) were included in the analysis. 2 studies were 3-arm trials and 1 was
a 4-arm trial.With placebo as the reference class, the OR ofmortalitywas 1.00 (0.06,
4.20) for prostanoids; 1.14 (0.15, 4.69) for endothelin-receptor antagonists and 0.62
(0.05, 2.83) for phosphodiesterase. Using prostanoids as the reference class, the OR
of mortality was 4.28 (0.10, 23.10) for endothelin-receptor antagonists and 2.40
(0.04, 12.66) for phosphodiesterase. Using endothelin-receptor antagonists as the
reference class, the OR of mortality was 1.11 (0.04, 5.55) for phosphodiesterase.
None of the ORs were statistically significant. CONCLUSIONS: Based on the risk of
mortality reported in clinical trials, there is no statistically significant difference
among PAH drug classes. Including more studies/drugs and the use of different
PAH outcomes could inform a more detailed comparison.
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PERSISTENCE WITH STATINS AND PRIMARY PREVENTION OF
CARDIOVASCULAR EVENTS: A POPULATION-BASED COHORT STUDY
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Maccabi Healthcare Services, Tel Aviv, Israel
OBJECTIVES: To evaluate the association between persistent use of statins and the
risk of acute cardiovascular events among primary prevention patients in commu-
nity settings. METHODS: A population-based retrospective cohort among 171,846
adults aged 45-75, with no history of any cardiovascular disease, who began statin
therapy between 1998 and 2009. Proportion of days covered (PDC) with statins was
measured by the number of dispensed prescriptions during follow-up period.
Study endpoint was occurrence of a major cardiovascular event, which comprised
myocardial infarction or performance of a cardiac revascularization procedure
RESULTS: The fully adjusted survival analysis indicated a significant negative as-
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